Efficacy and safety of a new 5% minoxidil formulation in male androgenetic alopecia: A randomized, placebo‐controlled, double‐blind, noninferiority study

    February 2019 in “Journal of Cosmetic Dermatology
    Ulrike Blume-Peytavi, Zahida Issiakhem, Stéphanie Gautier, Jan Kottner, Walter Wigger-Alberti, Tobias Fischer, Rolf Hoffmann, Françoise Tonner, Athmane Bouroubi, Jean-Jacques Voisard
    Image of study
    TLDR New 5% minoxidil formula safely and effectively treats male hair loss.
    The study evaluated the efficacy and safety of a new 5% minoxidil formulation, DC0120, in stimulating hair growth in men with androgenetic alopecia (AGA). The study was a randomized, double-blind, placebo-controlled trial involving 220-231 subjects. The results showed that DC0120 was noninferior to a marketed comparator (ALOSTIL®) in increasing nonvellus target area hair count (TAHC) and cumulative hair thickness density. The treatment-related adverse events were mild or moderate, and none could be attributed specifically to DC0120 or the comparator product. The study concluded that DC0120 is a safe and effective treatment for AGA in men.
    View this study on onlinelibrary.wiley.com →

    Cited in this study

    Related